Stem Cell Company Moves Closer to U.S. Cardiac Market
In its third quarter financial report, San Diego-based Cytori said it has moved significantly closer to initiating its cardiovascular clinical trials," said Christopher J. Calhoun, chief executive officer of Cytori Therapeutics. The company is developing adipose stem cells in cardiovascular disease and for use in reconstructive surgery.
"The first trial is expected to start before year end in patients suffering from chronic ischemia, a severe form of coronary artery disease, and the heart attack trial is expected to begin in early 2007.
Cytori received U.S. 510(K) regulatory clearance recently on the Celution Cell Concentration System as a cell saver device by the FDA's Center for Devices and Radiological Health (CDRH)
For more information visit www.cytoritx.com
More like this
- Cytori Stem, Regenerative Cell Heart Attack Trial Deemed Feasible, Safe
- Cytori Completes Enrollment in First Adipose Stem & Regenerative Cell Therapy Trial for Chronic Heart Disease
- Resurrecting Dead Heart Tissue
- New HF Procedure Uses Stem Cells from Patient’s Fat Tissue
- GE to Show Portfolio of Radiation Oncology Solutions at ASCO